A548DB97-6D28-4DEA-8334-201093A67B1E
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 65.34165571616295
- age_years
- 41
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.473
- HEDGEHOG_SIGNALING+0.449
- PANCREAS_BETA_CELLS+0.383
- WNT_BETA_CATENIN_SIGNALING+0.355
- G2M_CHECKPOINT+0.246
- MITOTIC_SPINDLE+0.243
- MYC_TARGETS_V2+0.167
- APICAL_SURFACE+0.122
- E2F_TARGETS+0.087
- TGF_BETA_SIGNALING+0.083
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.482
- OXIDATIVE_PHOSPHORYLATION-0.432
- IL6_JAK_STAT3_SIGNALING-0.395
- ANGIOGENESIS-0.390
- TNFA_SIGNALING_VIA_NFKB-0.381
- INTERFERON_GAMMA_RESPONSE-0.373
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.329
- INFLAMMATORY_RESPONSE-0.317
- IL2_STAT5_SIGNALING-0.312
- MYOGENESIS-0.312
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-56-8083-01A-11R-2247-07 | — | cohortMD1 | 0.861 |
| 2 | ERR2598237 | fetal | fetal | 0.860 |
| 3 | 0D8C7EC1-9BFB-44A1-8AF8-05D2A6BBE0F9 | — | — | 0.842 |
| 4 | A19ADC4B-C7E3-4855-9B59-009865D4FBF0 | — | — | 0.835 |
| 5 | 6819D9DA-FE18-4584-8AF6-E53DD894852E | — | — | 0.831 |
| 6 | 2c76906f-57a5-42b2-aa73-544814ea4657 | — | — | 0.830 |
| 7 | 167869B6-9620-445E-BA77-B6F95A6463F5 | — | — | 0.828 |
| 8 | SRR934858 | — | — | 0.819 |
| 9 | SRR8752373 | — | — | 0.808 |
| 10 | 2e15a781-21c1-421b-9e92-6d2d414e0d14 | — | — | 0.808 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.473 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.449 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.383 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.355 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.246 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.243 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.167 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.122 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.087 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.083 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.071 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.068 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.046 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.017 | Inavolisib | — uncovered |